---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-004096"
form_type: "8-K/A"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2024-07-05T23:59:59+00:00"
generated_at: "2026-05-31T23:22:17.666371+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# BioNexus Gene Lab Corp amends CEO/acting CFO compensation: base salary $35k/month effective July 1, 2024, plus back pay

## Summary
- Base salary for CEO/acting CFO Su-Leng Tan Lee set at $35,000 per month effective July 1, 2024.
- Company will recognize back pay at this rate from when Tan Lee began serving as CEO and CFO.
- Inducement Award Entitlement to be finalized by Compensation Committee in Q3 2024.
- Amendment approved by Compensation Committee on June 30, 2024.

## SEC filing metadata
- accession: 0001477932-24-004096
- form_type: 8-K/A
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2024-07-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793224004096/0001477932-24-004096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793224004096/bglc_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-004096
- JSON: https://secwatch.observer/filing/0001477932-24-004096.json
- Plain text: https://secwatch.observer/filing/0001477932-24-004096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.